Mark Plavsic - Mar 15, 2024 Form 3 Insider Report for Aura Biosciences, Inc. (AURA)

Role
Chief Technology Officer
Signature
/s/ Julie Feder, Attorney-in-fact
Stock symbol
AURA
Transactions as of
Mar 15, 2024
Transactions value $
$0
Form type
3
Date filed
3/25/2024, 04:01 PM
Previous filing
Jan 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AURA Common Stock 129K Mar 15, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AURA Stock Option (Right to Buy) Mar 15, 2024 Common Stock 138K $8.30 Direct F1
holding AURA Stock Option (Right to Buy) Mar 15, 2024 Common Stock 41.5K $7.77 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option vest as follows: 25% of the shares vest on September 25, 2024 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.
F2 The shares underlying this option vest as follows: 25% of the shares vest on February 1, 2025 with the remainder vesting thereafter pro-rata in 36 monthly installments, subject to the Reporting Person's continued service as of each such vesting date.

Remarks:

Exhibit 24.1 - Power of Attorney